Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155203 · ClinicalTrials.gov registry record · Phase 3
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions
A Phase 3 study of Secondarily Infected Traumatic Skin Lesions, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 657
- Enrollment target
- 1
- Study location
NCT04155203 is a Phase 3 study of Secondarily Infected Traumatic Skin Lesions that has completed, run by Padagis. The registered enrollment target is 657 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04155203, a Phase 3 study of Secondarily Infected Traumatic Skin Lesions, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 657 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the safety and efficacy of Perrigo's product to an FDA approved product, and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG Mupirocin Calcium
Study Locations (1)
Florida
- Palm Beach Research Center - West Palm Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 657 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2021-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04155203
The ClinicalTrials.gov registry entry for NCT04155203 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 657 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Secondarily Infected Traumatic Skin Lesions appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT04155203 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04155203 about?
NCT04155203 is a clinical study titled "To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions". To compare the safety and efficacy of Perrigo's product to an FDA approved product, and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions
What is the current status of trial NCT04155203?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 657 participants. The study started on 2019-10-15. Estimated completion is 2021-06-01.
What conditions does trial NCT04155203 study?
This clinical trial studies the following conditions: Secondarily Infected Traumatic Skin Lesions.
What interventions are being tested in trial NCT04155203?
The interventions under investigation include: Vehicle (DRUG), Mupirocin Calcium (DRUG).
Who is sponsoring clinical trial NCT04155203?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04155203 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.